Table 2:

Prospective trials in oligometastatic prostate cancer

Study	Population	Outcome
Palma et al.	Oligorecurrent disease (≤ 5 metastases) Randomized SOC palliation +/− MDT	Median OS (41 vs 28 months)
		Median PFS (12 vs 6 months)
Ost et al.	Oligorecurrent HSPC (≤ 3 metastases), No ADT, Randomized MDT vs observation	Median ADT-FS (21 vs 13 months)
Siva et al.	Oligorecurrent HSPC and CRPC (≤ 3 metastases), Single arm SABR, No ADT for HSPC	One (58%) and two year (39%) DPFS
		Two year ADT-FS (48%)
Kneebone et al.	Oligorecurrent HSPC (≤ 3 metastases), Single arm SABR, PSMA scan used, No ADT	Median bDFS (11 months)
Bowden et al.	Oligorecurrent (≤ 5 metastases), majority HSPC; single arm SABR, no ADT for HSPC	Two year FFTE (51.7%)
ORIOLE	Oligorecurrent HSPC (≤ 3 metastases), Randomized SABR vs observation; No ADT	Pending
Boeve et al.	De novo metastatic PCa randomized to ADT +/− RT to prostate primary	Median OS (45 vs 43 months)
		Trend to improved OS with < 5 lesions
Parker et al	De novo metastatic PCa randomized to ADT +/− RT to prostate primary	Median OS (46 vs 48 months)
		Three year OS improved in low (81 vs 73%), but not high volume disease*

NSCLC – Non small cell lung cancer; LC – local consolidation; chemo – chemotherapy, OS – overall survival; PFS – progression free survival; MDT – metastasis directed therapy; SOC – standard of care; bDFS – biochemical disease free survival, FFTE – freedom from treatment escalation

^*High volume defined as four or more bone metastases with at least one outside the vertebrae/pelvis or visceral metastases